Dystonia

Botulinum Toxin Type B for Dystonia

On December 11, 2000, a botulinum toxin type B product (Myobloc™) was approved by the FDA in the United States as a treatment for patients with cervical dystonia. Myobloc™ is the U.S. trade name for Solstice Neurosciences' botulinum toxin type B product. This product also received marketing authorization from the European Union's Committee for Proprietary Medicinal Products and is available there as Neurobloc®.

Safety and efficacy were demonstrated in double-blind clinical trials in patients who had responded to BTX-A and in patients who had developed resistance to BTX-A. BTX-A and BTX-B have slightly different chemical structures and their primary mechanisms of action on acetylcholine also differ. The appropriateness of BTX-B–or of any dystonia therapy–relies on its ability to meet the goals of patients and caregivers as outlined in their comprehensive treatment plan.

See E-MOVE Article: BTX-B for cervical dystonia (AAN report)

1. Safety and efficacy of Neurobloc® (botulinum toxin type-B) in type-A resistant cervical dystonia (CD) patients
2. Safety and efficacy of Neurobloc® (botulinum toxin type-B) in type-A responsive cervical dystonia patients